{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-250130","form_type":"8-K","ticker":"CELU","cik":"0001752828","company_name":"Celularity Inc","filed_at":"2022-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.908960+00:00","generated_at":"2026-06-23T07:47:48.708411+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Celularity retains former President Dr. Pecora as consultant and advisory co-chair","bullets":["Dr. Pecora resigned as President effective Aug 31, 2022; consulting agreement signed Sept 21, 2022.","Consulting fee: $10,000/month for six-month term, automatically renews for one additional six-month term.","Separate scientific/clinical advisor agreement effective Sept 1, 2022: $10,000/month plus $125,000 in RSUs vesting over four years.","Advisor agreement has a one-year term and may be renewed annually by mutual agreement.","No other executive changes disclosed; Pecora remains involved in clinical development and advisory board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-250130","json":"https://secwatch.observer/filing/0001193125-22-250130.json","markdown":"https://secwatch.observer/filing/0001193125-22-250130.md","text":"https://secwatch.observer/filing/0001193125-22-250130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1752828/000119312522250130/0001193125-22-250130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1752828/000119312522250130/d255337d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T07:47:48.708411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8f64385476","claim":"Andrew L. Pecora resigned as President at Celularity Inc.","evidence_excerpt":"As previously disclosed in the Current Report on Form 8-K filed by Celularity Inc, or Celularity, with the Securities and Exchange Commission, or the SEC, on July 20, 2022, Andrew L. Pecora, M.D., F.A.C.P., resigned as Celularity’s President effective as of August 31, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1752828/000119312522250130/0001193125-22-250130-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}